developed a deformable liposome system (D‐Lipo) to co‐deliver Vor and Siv for treating the NSCLC.[144] In vitro, Vor treatment alone could obviously decrease M2‐related CD206 maker via inhibiting HDAC2 expression and STAT6 phosphorylation. Here, HDAC2 is linked to non-small cell lung carcinoma.